A Delaware judge dismissed a former Aurion Biotech executive's challenge to a stockholder's alleged takeover of the company, ...

Massachusetts biotech IPOs are on their way to surpassiing 2020 and 2021 records, with $3.2 billion raised in just six months ...

Cambridge biotech Alopexx Inc. has filed paperwork with the U.S. Securities and Exchange Commission to go public on the NYSE ...

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

If you’ve been tracking last week’s initial public offering of SpaceX, and the forthcoming IPOs of OpenAI and Anthropic, it’s a little like staring into the sun: everything else looks a little washed ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the ...

It's important to consider your comfort with risk before diving in.

Kardigan Inc. shares surged 38% in its trading debut, after the heart-health focused biotech raised $400 million in an ...

While the SpaceX IPO may be in the rearview mirror, its trading still dominated financial headlines this week. Read more here.

New biotech stock Kardigan may reveal Wall Street’s next move ...